mAbxience and Abdi İbrahim Announce Landmark Technology Transfer Agreement, Advancing Biotechnology in TürkiyeMiguel Martínez-Cava2023-11-20T08:43:23+01:00November 20, 2023|Press releases|
mAbxience and MS Pharma Sign Partnership for Denosumab Biosimilar in Select MEA CountriesMiguel Martínez-Cava2023-11-13T07:53:41+01:00November 13, 2023|Press releases|
mAbxience and Amneal Strengthen Alliance with Two Denosumab Biosimilars in the U.S. for the Treatment of Oncology and Bone DiseasesClara Prieto2023-10-21T14:44:19+02:00October 12, 2023|Press releases|
Celebrating Emmanuelle Lepine’s Legacy of Excellence at mAbxienceMiguel Martínez-Cava2024-01-15T07:54:41+01:00January 15, 2024|News|
Boosting biologics and Contract Manufacturing at mAbxience facilitiesComunicacion Admon2023-04-03T09:26:50+02:00April 3, 2023|News|
HK inno.N licenses in mAbxience’s denosumab biosimilartheoms2023-01-25T10:46:18+01:00January 25, 2023|News|